New two-year data confirm Roche’s Vabysmo improves vision with fewer treatments for people with neovascular age-related macular degeneration July 14, 2022July 14, 2022 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: New two-year data for Roche’s Vabysmo and Susvimo…New two-year data for Roche’s Vabysmo and Susvimo…FDA accepts application for Roche’s faricimab for…FDA accepts application for Roche’s Port Delivery…FDA approves Roche’s Susvimo, a first-of-its-kind…The Lancet publishes studies showing Roche’s…Share this:Click to share on Twitter (Opens in new window)Click to share on Facebook (Opens in new window)
